Mylan unveils generic Apresoline Injection for treatment of severe essential hypertension.
M2 EQUITYBITES-May 6, 2016-Mylan unveils generic Apresoline Injection for treatment of severe essential hypertension
(C)2016 M2 COMMUNICATIONS http://www.m2.com
Pharmaceutical company Mylan NV (Nasdaq:MYL) (TASE:MYL) revealed on Thursday the availability of Hydralazine Hydrochloride Injection USP, 20 mg/ml in the US market.
The company added the Hydralazine Hydrochloride Injection USP, 20 mg/ml is a generic version of Novartis' Apresoline Injection, 20 mg/ml.
According to the company, it has received the final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Hydralazine Hydrochloride Injection USP for severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.
For the 12 months ending 31 March 2016, Hydralazine Hydrochloride Injection USP, 20 mg/ml, had US sales of about USD63.4m, according to IMS Health.
In conjunction, the launch of Hydralazine Hydrochloride Injection adds to the company's growing portfolio of more than 150 injectable products available to patients in the US across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Article Type:||Disease/Disorder overview|
|Date:||May 6, 2016|
|Previous Article:||The Rockefeller University names Richard P Lifton MD PhD as 11th president.|
|Next Article:||HealthSouth's board announces USD0.23 per share dividend.|